View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi S. 2/A 1083
  • | 2 Csolnoky Ferenc Megyei Kórház I. Belgyógyászati Osztály Veszprém
Open access

Az 5-aminoszalicilsav- (5-ASA-) készítmények mind a mai napig a colitis ulcerosa terápiájának alapvető gyógyszereit jelentik. Számos orálisan adható 5-ASA-készítmény van forgalomban, beleértve az azo-kötést tartalmazó prodrugokat (például sulfalazin, olsalazin, balzalazid), valamint a mesalazin elnyújtott és kontrollált hatóanyag-kibocsátású kiszereléseit. Az orális terápia hatékonysága a beteg jó együttműködésén is múlik, amelynek gátat szabhat a naponta többször adott, nagyszámú tabletta bevétele. Ez a tényező a colitis ulcerosában szenvedő betegek terápiájának pontos betartásában jelentős akadályt képezhet. A közelmúltban egy új, naponta egyszer adandó, egyedülálló multimátrix mesalazinkészítmény és a szintén naponta egy alkalommal adható mesalazingranulátum hatékonynak bizonyult az enyhe-közepes súlyosságú colitis ulcerosa indukciós és fenntartó terápiájában. A mellékhatásprofil ugyanakkor nem különbözött a hagyományos mesalazinkészítményektől. A ritka adagolás a betegek jobb hosszú távú compliance-e által hozzájárulhat a betegek hatékonyabb kezeléséhez és várhatóan a colitis ulcerosával kapcsolatos colorectalis carcinoma rizikójának csökkentéséhez. A szerzők az alábbi közleményben összefoglalják az új, naponta egyszer adandó mesalazinkészítmények rövid és közepes távú hatékonyságával és biztonságosságával kapcsolatban elérhető irodalmi adatokat.

  • Lakatos, P. L., Fischer, S., Lakatos, L. és mtsai: Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take “toll”? World J. Gastroenterol., 2006, 12 , 1829–1840.

    Lakatos L. , 'Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take “toll”? ' (2006 ) 12 World J. Gastroenterol. : 1829 -1840.

    • Search Google Scholar
  • Lakatos, P. L.: Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J. Gastroenterol., 2006, 12 , 6102–6108.

    Lakatos P. L. , 'Recent trends in the epidemiology of inflammatory bowel diseases: up or down? ' (2006 ) 12 World J. Gastroenterol. : 6102 -6108.

    • Search Google Scholar
  • Travis, S. P. L., Stange, E. F., Lémann, M. és mtsai: European evidence-based consensus on the management of ulcerative colitis, current management. J. Crohn Colitis, 2008, 2 , 24–62.

    Lémann M. , 'European evidence-based consensus on the management of ulcerative colitis, current management ' (2008 ) 2 J. Crohn Colitis : 24 -62.

    • Search Google Scholar
  • Safdi, M., DeMicco, M., Sninsky, C. és mtsai: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol., 1997, 92 , 1867–187.

    Sninsky C. , 'A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis ' (1997 ) 92 Am. J. Gastroenterol. : 1867 -187.

    • Search Google Scholar
  • Sutherland, L., MacDonald, J. K.: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2006, 2 , CD000543.

    MacDonald J. K. , 'Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis ' (2006 ) 2 Cochrane Database Syst. Rev. : CD000543 -.

    • Search Google Scholar
  • Ransford, R. A., Langman, M. J.: Sulphasalazine and mesalazine, serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut, 2002, 51 , 536–539.

    Langman M. J. , 'Sulphasalazine and mesalazine, serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines ' (2002 ) 51 Gut : 536 -539.

    • Search Google Scholar
  • Desreumaux, P., Ghosh, S.: Review article, mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment. Pharmacol. Ther., 2006, 24 (Suppl. 1) , 2–9.

    Ghosh S. , 'Review article, mode of action and delivery of 5-aminosalicylic acid – new evidence ' (2006 ) 24 Aliment. Pharmacol. Ther. : 2 -9.

    • Search Google Scholar
  • McCormack, P. L., Robinson, D. M., Perry, C. M.: Delayed-release multi matrix system (MMXTM) mesalazine in ulcerative colitis. Drugs, 2007, 67 , 2635–2642.

    Perry C. M. , 'Delayed-release multi matrix system (MMXTM) mesalazine in ulcerative colitis ' (2007 ) 67 Drugs : 2635 -2642.

    • Search Google Scholar
  • Kane, S. V., Cohen, R. D., Aikens, J. E. és mtsa: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol., 2001, 96 , 2929–2933.

    Aikens J. E. , 'Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis ' (2001 ) 96 Am. J. Gastroenterol. : 2929 -2933.

    • Search Google Scholar
  • Cervený, P., Bortlík, M., Kubena, A. és mtsai: Nonadherence in inflammatory bowel disease, results of factor analysis. Inflamm. Bowel Dis., 2007, 13 , 1244–1249.

    Kubena A. , 'Nonadherence in inflammatory bowel disease, results of factor analysis ' (2007 ) 13 Inflamm. Bowel Dis. : 1244 -1249.

    • Search Google Scholar
  • Su, C., Lewis, J. D., Goldberg, B. és mtsai: A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis. Gastroenterology, 2007, 132 , 516–526.

    Goldberg B. , 'A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis ' (2007 ) 132 Gastroenterology : 516 -526.

    • Search Google Scholar
  • Prakash, A., Markham, A.: Oral delayed-release mesalazine, a review of its use in ulcerative colitis and Crohn’s disease. Drugs, 1999, 57 , 383–408.

    Markham A. , 'Oral delayed-release mesalazine, a review of its use in ulcerative colitis and Crohn’s disease ' (1999 ) 57 Drugs : 383 -408.

    • Search Google Scholar
  • Bantel, H., Berg, C., Vieth, M. és mtsai: Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol., 2000, 95 , 3452–3457.

    Vieth M. , 'Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis ' (2000 ) 95 Am. J. Gastroenterol. : 3452 -3457.

    • Search Google Scholar
  • Rousseaux, C., Lefebvre, B., Dubuquoy, L. és mtsai: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med., 2005, 201 , 1205–1215.

    Dubuquoy L. , 'Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma ' (2005 ) 201 J. Exp. Med. : 1205 -1215.

    • Search Google Scholar
  • Osawa, E., Nakajima, A., Wada, K. és mtsai: Peroxysome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology, 2003, 124 , 361–367.

    Wada K. , 'Peroxysome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice ' (2003 ) 124 Gastroenterology : 361 -367.

    • Search Google Scholar
  • Brunner, M., Assandri, R., Kletter, K. és mtsai: Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther., 2003, 17 , 395–402.

    Kletter K. , 'Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation ' (2003 ) 17 Aliment. Pharmacol. Ther. : 395 -402.

    • Search Google Scholar
  • Shire Pharmaceuticals, Inc., Lialda TM, prescribing information. Wayne, PA, Shire Pharmaceuticals, 2007.

  • Sandborn, W. J., Hanauer, S. B.: Systematic review, the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther., 2003, 17 , 29–42.

    Hanauer S. B. , 'Systematic review, the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis ' (2003 ) 17 Aliment. Pharmacol. Ther. : 29 -42.

    • Search Google Scholar
  • D’Haens, G., Hommes, D., Engels, L. és mtsai: Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis, a phase II, dose-ranging study. Aliment. Pharmacol. Ther., 2006, 24 , 1087–1097.

    Engels L. , 'Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis, a phase II, dose-ranging study ' (2006 ) 24 Aliment. Pharmacol. Ther. : 1087 -1097.

    • Search Google Scholar
  • Pierce, D., Martin, P., Kern, M. és mtsa: MMXTM mesalazine, a pharmacokinetic evaluation of dose proportionality and the effect of food. Gut, 2007, 56 (Suppl. III) , A158.

    Kern M. , 'MMXTM mesalazine, a pharmacokinetic evaluation of dose proportionality and the effect of food ' (2007 ) 56 Gut : A158 -.

    • Search Google Scholar
  • Dilger, K., Baumgaertner, E., Thomann, P.: Once-daily oral mesalazine (1.5 g/day or 3.0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial. Gut, 2007, 56 (Suppl. III) , A150.

    Thomann P. , 'Once-daily oral mesalazine (1.5 g/day or 3.0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial ' (2007 ) 56 Gut : A150 -.

    • Search Google Scholar
  • Prantera, C., Viscido, A., Biancone, L. és mtsai: A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm. Bowel Dis., 2005, 11 , 421–427.

    Biancone L. , 'A new oral delivery system for 5-ASA: preliminary clinical findings for MMx ' (2005 ) 11 Inflamm. Bowel Dis. : 421 -427.

    • Search Google Scholar
  • Lichtenstein, G. R., Kamm, M. A., Boddu, P. és mtsai: Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol., 2007, 5 , 95–102.

    Boddu P. , 'Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis ' (2007 ) 5 Clin. Gastroenterol. Hepatol. : 95 -102.

    • Search Google Scholar
  • Kamm, M. A., Sandborn, W. J., Gassull, M. és mtsai: Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology, 2007, 132 , 66–75.

    Gassull M. , 'Once-daily, high-concentration MMX mesalamine in active ulcerative colitis ' (2007 ) 132 Gastroenterology : 66 -75.

    • Search Google Scholar
  • Sandborn, W. J., Kamm, M. A., Lichtenstein, G. R. és mtsai: MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis, a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther., 2007, 26 , 205–215.

    Lichtenstein G. R. , 'MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis, a combined analysis of two randomized, double-blind, placebo-controlled trials ' (2007 ) 26 Aliment. Pharmacol. Ther. : 205 -215.

    • Search Google Scholar
  • Schreiber, S., Karlstadt, R., Barrett, K. és mtsa: MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis, time to initial symptom resolution. Gut, 2007, 56 (Suppl. III) , A160.

    Barrett K. , 'MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis, time to initial symptom resolution ' (2007 ) 56 Gut : A160 -.

    • Search Google Scholar
  • Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J. és mtsai: MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis, efficacy and tolerability in specific patient subpopulations. Aliment. Pharmacol. Ther., 2008, 27 , 1094–1102.

    Sandborn W. J. , 'MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis, efficacy and tolerability in specific patient subpopulations ' (2008 ) 27 Aliment. Pharmacol. Ther. : 1094 -1102.

    • Search Google Scholar
  • Kruis, W., Gorelov, A., Kiudelis, G. és mtsai: Once daily dosing of 3 g mesalamine (Salofalk granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis. Gastroenterology, 2007, 132 (Suppl. S) , 898.

    Kiudelis G. , 'Once daily dosing of 3 g mesalamine (Salofalk granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis ' (2007 ) 132 Gastroenterology : 898 -.

    • Search Google Scholar
  • Kruis, W., Greinwald, R., Mueller, R.: Factors influencing therapeutic efficacy of mesalamine (Salofalk Granules) in active ulcerative colitis, a combined analysis from 3 pivotal controlled studies. Gut, 2007, 56 (Suppl. S) , A156.

    Mueller R. , 'Factors influencing therapeutic efficacy of mesalamine (Salofalk Granules) in active ulcerative colitis, a combined analysis from 3 pivotal controlled studies ' (2007 ) 56 Gut : A156 -.

    • Search Google Scholar
  • Kamm, M. A., Lichtenstein, G. R., Sandborn, W. J. és mtsai: Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut, 2008, 57 , 893–902.

    Sandborn W. J. , 'Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis ' (2008 ) 57 Gut : 893 -902.

    • Search Google Scholar
  • Kamm, M. A., Hanauer, S. B., Lichtenstein, G. R. és mtsai: MMX mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis, outcome in patients treated over 14-16 months. Gastroenterology, 2007, 132 (Suppl. S) , T1297.

    Lichtenstein G. R. , 'MMX mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis, outcome in patients treated over 14-16 months ' (2007 ) 132 Gastroenterology : T1297 -.

    • Search Google Scholar
  • The mesalamine Study Group: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis, a randomized placebo-controlled trial. Ann. Intern. Med., 1996, 124 , 204–211.

    'An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis, a randomized placebo-controlled trial ' (1996 ) 124 Ann. Intern. Med. : 204 -211.

    • Search Google Scholar
  • Lichtenstein, G. R., Diebold, R., Karlstadt, R. G. és mtsai: Patients with quiescent mild-to-moderate ulcerative colitis receiving a multiple-daily dose 5-aminosalicylic acid formulation can maintain remission with once- or twice-daily MMX mesalamine. Gastroenterology, 2007, 132 (Suppl. S) , T1295.

    Karlstadt R. G. , 'Patients with quiescent mild-to-moderate ulcerative colitis receiving a multiple-daily dose 5-aminosalicylic acid formulation can maintain remission with once- or twice-daily MMX mesalamine ' (2007 ) 132 Gastroenterology : T1295 -.

    • Search Google Scholar
  • Lichtenstein, G. R., Diebold, R., Karlstadt, R. G. és mtsai: The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to moderate ulcerative colitis. Gastroenterology, 2007, 132 (Suppl. S) , T1284.

    Karlstadt R. G. , 'The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to moderate ulcerative colitis ' (2007 ) 132 Gastroenterology : T1284 -.

    • Search Google Scholar
  • Kamm, M. A., Hanauer, S. B., Diebold, R. és mtsai: Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX mesalazine and subsequent long-term remission rates, results from three international combined acute and maintenace studies. Gut, 2007, 56 (Suppl. III) , A154.

    Diebold R. , 'Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX mesalazine and subsequent long-term remission rates, results from three international combined acute and maintenace studies ' (2007 ) 56 Gut : A154 -.

    • Search Google Scholar
  • Prantera, C., Kohn, A., Campieri, M. és mtsai: Once daily MMX 5-aminosalicylic acid versus twice-daily Asacol for the maintenance of remission of ulcerative colitis. Gastroenterology, 2008, 134 (Suppl. S) , T1136.

    Campieri M. , 'Once daily MMX 5-aminosalicylic acid versus twice-daily Asacol for the maintenance of remission of ulcerative colitis ' (2008 ) 134 Gastroenterology : T1136 -.

    • Search Google Scholar
  • Dignass, A., Vermeire, S., Adamek, H. és mtsai: Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis, results from a multinational randomised controlled trial. Gut, 2007, 56 , OP-G-378.

    Adamek H. , 'Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis, results from a multinational randomised controlled trial ' (2007 ) 56 Gut : OP-G-378 -.

    • Search Google Scholar
  • Kruis, W., Laimas, J., Pokrotnieks, J. és mtsai: Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis. A double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology, 2008, 134 (Suppl. S) , T1124.

    Pokrotnieks J. , 'Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis. A double-blind, double-dummy, randomized, controlled, dose-ranging study ' (2008 ) 134 Gastroenterology : T1124 -.

    • Search Google Scholar
  • Loftus, E. V.: Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroent. Clin. North Am., 2006, 35 , 517–531.

    Loftus E. V. , 'Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis ' (2006 ) 35 Gastroent. Clin. North Am. : 517 -531.

    • Search Google Scholar
  • Lakatos, L., Mester, G., Erdelyi, Z. és mtsai: Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis, results of a population-based study. Inflamm. Bowel Dis., 2006, 12 , 205–211.

    Erdelyi Z. , 'Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis, results of a population-based study ' (2006 ) 12 Inflamm. Bowel Dis. : 205 -211.

    • Search Google Scholar
  • Velayos, F. S., Terdiman, J. P., Walsh, J. M.: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk, a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol., 2005, 100 , 1345–1353.

    Walsh J. M. , 'Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk, a systematic review and metaanalysis of observational studies ' (2005 ) 100 Am. J. Gastroenterol. : 1345 -1353.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 0 3 27
Feb 2021 0 1 18
Mar 2021 0 5 23
Apr 2021 0 6 30
May 2021 0 3 18
Jun 2021 0 2 12
Jul 2021 0 0 0